GRFS240816P12500
- 2.34
- 0.000.00%
Grifols Newsroom
Grifols Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS)
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Grifols SA (GRFS)
Kepler Capital Reaffirms Their Buy Rating on Grifols SA (GRFS)
Kepler Capital Sticks to Its Buy Rating for Grifols SA (GRFS)
Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Grifols SA (GRFS)
Kepler Capital Reaffirms Their Buy Rating on Grifols SA (GRFS)
Kepler Capital Keeps Their Buy Rating on Grifols SA (GRFS)
JP Morgan Maintains Neutral on Grifols, Raises Price Target to $10.5
Grifols Analyst Ratings
Kepler Capital Remains a Buy on Grifols SA (GRFS)
Kepler Capital Sticks to Their Buy Rating for Grifols SA (GRFS)
Kepler Capital Sticks to Their Buy Rating for Grifols SA (GRFS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Grifols SA (GRFS) and Cochlear Limited (OtherCHEOF)
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Grifols SA (GRFS)
Analysts Offer Insights on Healthcare Companies: Grifols SA (GRFS) and Medios AG (OtherMEDOF)
Analysts Offer Insights on Healthcare Companies: Grifols SA (GRFS) and Elevance Health (ELV)
Grifols Upgraded to Overweight at Morgan Stanley
Credit Suisse Reinstates Grifols With Neutral Rating, EUR10 Price Target; Sees Improving Plasma Collection Dynamics Offset by High Debt
Grifols SA (GRFS) Was Upgraded to a Buy Rating at Kepler Capital